Seelos Therapeutics (SEEL)

Company Profile

seelos therapeutics, inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. the company's lead programs are sls-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorder and post-traumatic stress disorder; sls-005, a protein stabilizer for the treatment of sanfilippo syndrome; and sls-006, a partial dopamine agonist for the treatment of patients with parkinson's disease (pd). its preclinical programs include sls-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with pd; sls-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; sls-004 for the treatment of pd; sls-010, an oral histamine h3a receptor antagonist for narcolepsy a

Company profile

Ticker

SEEL

Exchange

NASDAQ

Website

seelostherapeutics.com/

CEO

Raj Mehra

Incorporated

Nevada

Location

New York

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Bausch Health Companies • Celgene ...

Former names

APRICUS BIOSCIENCES, INC., NEXMED INC

SEC CIK

0001017491

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

NexMed (U.S.A.), Inc. • Apricus Pharmaceuticals USA, Inc. • NexMed Holdings, Inc. • NexMed International Limited • Seelos Corporation • Seelos Therapeutics Australia Pty Ltd ...

IRS number

870449967

SEEL stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

424B5

Prospectus supplement for primary offering

28 Nov 23

424B3

Prospectus supplement

28 Nov 23

8-K

Material Modifications to Rights of Security Holders

28 Nov 23

8-K

Seelos Therapeutics Announces 1-for-30 Reverse Stock Split

24 Nov 23

8-K

Seelos Therapeutics Announces 1-for-30 Reverse Stock Split

14 Nov 23

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

3 Nov 23

8-K

Entry into a Material Definitive Agreement

2 Oct 23

EFFECT

Notice of effectiveness

2 Oct 23

424B3

Prospectus supplement

29 Sep 23

Transcripts

SEEL

Earnings call transcript

2017 Q4

1 Mar 18

SEEL

Earnings call transcript

2017 Q3

5 Nov 17

Latest ownership filings

View all

Michael Joseph Golembiewski

1 Sep 23

Raj Mehra

31 Mar 23

Michael Joseph Golembiewski

31 Mar 23

Michael Joseph Golembiewski

Financial summary

Financial statements Chart SEEL financial data

Quarter (USD)	Sep 23	Jun 23	Mar 23	Dec 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	2.58 mm	2.58 mm	2.58 mm	2.58 mm	2.58 mm	2.58 mm
Cash burn (monthly)	1.09 mm	2.33 mm	4.20 mm	4.23 mm	1.92 mm	2.92 mm
Cash used (since last report)	2.16 mm	4.63 mm	8.36 mm	8.41 mm	3.81 mm	5.82 mm
Cash remaining	422.31 k	-2.05 mm	-5.78 mm	-5.83 mm	-1.23 mm	-3.23 mm
Runway (months of cash)	0.4	-0.9	-1.4	-1.4	-0.6	-1.1

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2023

SEEL institutional ownership history Ownership history

15.0% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	82	80	+2.5%
Opened positions	10	11	-9.1%
Closed positions	8	10	-20.0%
Increased positions	18	13	+38.5%
Reduced positions	16	20	-20.0%

13F shares	Current	Prev Q	Change
Total value	25.94 bn	14.19 bn	+82.7%
Total shares	24.22 mm	22.54 mm	+7.5%
Total puts	73.70 k	77.80 k	-5.3%
Total calls	212.50 k	225.60 k	-5.8%
Total put/call ratio	0.3	0.3	+0.6%

Largest owners	Shares	Value	Change
Gendell Jeffrey L	5.17 mm	$6.18 bn	+2.0%
Vanguard	5.00 mm	$5.97 bn	-0.4%
LGND Ligand Pharmaceuticals	2.22 mm	$3.51 mm	0.0%
BLK Blackrock	1.68 mm	$2.01 bn	+1.2%
Wealth Effects	1.62 mm	$1.94 bn	+69.7%
Geode Capital Management	1.17 mm	$1.39 bn	+2.5%
Uniplan Investment Counsel	1.12 mm	$1.33 bn	-0.3%
Mirae Asset Global Investments	1.03 mm	$1.23 bn	-28.9%
Modera Wealth Management	871.51 k	$1.04 bn	0.0%
Woodline Partners	573.99 k	$685.91 mm	NEW

Largest transactions	Shares	Bought/sold	Change
Wealth Effects	1.62 mm	+666.50 k	+69.7%
Woodline Partners	573.99 k	+573.99 k	NEW
Millennium Management	466.74 k	+466.74 k	NEW
Mirae Asset Global Investments	1.03 mm	-417.47 k	-28.9%
EP Wealth Advisors	195.40 k	+190.28 k	+3719.4%
AdvisorShares Investments	295.20 k	-103.93 k	-26.0%
Gendell Jeffrey L	5.17 mm	+100.00 k	+2.0%
Susquehanna International	53.05 k	+53.05 k	NEW
Belpointe Asset Management	0.00	-50.00 k	EXIT
Gsa Capital Partners	48.02 k	+48.02 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

SEEL insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
31 Aug 23	Michael Joseph Golembiewski	Common Stock	Grant	Acquire A	No	No	0.618	12,500	7.73 k	103,487
30 Mar 23	Michael Joseph Golembiewski	Stock Option Common Stock	Grant	Acquire A	No	No	0.69	88,030	60.74 k	88,030
30 Mar 23	Michael Joseph Golembiewski	Stock Option Common Stock	Grant	Acquire A	No	No	0.69	677,701	467.61 k	677,701
30 Mar 23	Mehra Raj	Stock Option Common Stock	Grant	Acquire A	No	No	0.69	200,000	138.00 k	200,000
30 Mar 23	Mehra Raj	Stock Option Common Stock	Grant	Acquire A	No	No	0.69	1,682,300	1.16 mm	1,682,300
28 Feb 23	Michael Joseph Golembiewski	Common Stock	Grant	Acquire A	No	No	0.672	12,500	8.40 k	90,987
5 Jan 23	Lian Brian	Stock Option Common Stock	Grant	Acquire A	No	No	0.81	50,000	40.50 k	50,000